Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

STRATA Skin Sciences (SSKN) Total Current Liabilities (2016 - 2025)

STRATA Skin Sciences (SSKN) has disclosed Total Current Liabilities for 14 consecutive years, with $26.7 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities rose 99.62% to $26.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $26.7 million through Dec 2025, up 99.62% year-over-year, with the annual reading at $26.7 million for FY2025, 99.62% up from the prior year.
  • Total Current Liabilities hit $26.7 million in Q4 2025 for STRATA Skin Sciences, up from $15.0 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $26.7 million in Q4 2025 to a low of $11.3 million in Q2 2024.
  • Historically, Total Current Liabilities has averaged $14.4 million across 5 years, with a median of $13.4 million in 2022.
  • Biggest five-year swings in Total Current Liabilities: tumbled 34.94% in 2021 and later soared 99.62% in 2025.
  • Year by year, Total Current Liabilities stood at $12.8 million in 2021, then rose by 4.87% to $13.4 million in 2022, then dropped by 9.33% to $12.2 million in 2023, then increased by 10.04% to $13.4 million in 2024, then skyrocketed by 99.62% to $26.7 million in 2025.
  • Business Quant data shows Total Current Liabilities for SSKN at $26.7 million in Q4 2025, $15.0 million in Q3 2025, and $12.6 million in Q2 2025.